• +1-646-491-9876
    • +91-20-67278686

    Search

    Hidradenitis Suppurativa - Pipeline Review, H1 2017

    Hidradenitis Suppurativa - Pipeline Review, H1 2017

    • Report Code ID: RW0001689372
    • Category Healthcare
    • No. of Pages 92
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa - Pipeline Review, H1 2017, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

    Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 2, 4, 1, 8 and 1 respectively.

    Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
    - The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Hidradenitis Suppurativa - Overview
    Hidradenitis Suppurativa - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Hidradenitis Suppurativa - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Hidradenitis Suppurativa - Companies Involved in Therapeutics Development
    AbbVie Inc
    Amgen Inc
    Celgene Corp
    Cell Medica Ltd
    Cellceutix Corp
    Coherus BioSciences Inc
    InflaRx GmbH
    NeuClone Pty Ltd
    Novartis AG
    Panacea Biotec Ltd
    Sandoz International GmbH
    XBiotech Inc
    Hidradenitis Suppurativa - Drug Profiles
    adalimumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adalimumab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    apremilast - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    brilacidin tetrahydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CJM-112 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DLX-105 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DLX-2751 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IFX-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MABp-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Hidradenitis Suppurativa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Disrupt Cell Membrane for Hidradenitis Suppurativa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Hidradenitis Suppurativa - Dormant Projects
    Hidradenitis Suppurativa - Discontinued Products
    Hidradenitis Suppurativa - Product Development Milestones
    Featured News & Press Releases
    Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa
    Jan 04, 2017: InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa
    Nov 14, 2016: AbbVie's HUMIRA (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
    Sep 26, 2016: AbbVie To present New Data on HUMIRA (adalimumab) at the 25th European Academy of Dermatology and Venereology Congress
    Aug 03, 2016: Clinical trial results support adalimumab treatment for painful skin condition
    May 09, 2016: Scottish Medicines Consortium (SMC) accepts Humira (adalimumab) as the first approved treatment for the painful, chronic skin condition hidradenitis suppurativa for patients in Scotland
    May 04, 2016: NICE recommends Humira (adalimumab) as the first approved treatment for skin condition hidradenitis suppurativa in England and Wales
    Mar 02, 2016: Abbvie Announces New Dermatology Research From More Than 35 Presentations On Humira (Adalimumab), Long-Term And Real-World Data At The American Academy Of Dermatology 2016 Annual Meeting
    Jan 06, 2016: AbbVie HUMIRA (Adalimumab) Receives First and Only Health Canada Approval for Moderate to Severe Hidradenitis Suppurativa
    Oct 05, 2015: AbbVie Demonstrates Leadership in Dermatology with 26 Abstracts at the European Academy of Dermatology and Venereology Congress
    Sep 10, 2015: Abbvie's Humira (Adalimumab) Receives First And Only U.S. Food And Drug Administration Approval For Moderate To Severe Hidradenitis Suppurativa
    Jul 30, 2015: Humira (Adalimumab) Approved By European Commission For Moderate To Severe Hidradenitis Suppurativa
    Jun 26, 2015: Abbvie's Humira (Adalimumab) Receives Positive Chmp Opinion To Treat Adult Patients With Active Moderate To Severe Hidradenitis Suppurativa, A Chronic Inflammatory Skin Disease
    May 15, 2015: Abbvie Receives Orphan Drug Designation For Humira (Adalimumab) From The U.S. Food And Drug Administration For The Investigational Treatment Of Moderate-To-Severe Hidradenitis Suppurativa
    Mar 17, 2015: Abbvie's Dermatology Leadership Showcased With Humira (Adalimumab) Data At American Academy Of Dermatology 2015 Annual Meeting
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Hidradenitis Suppurativa, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hidradenitis Suppurativa - Pipeline by AbbVie Inc, H1 2017
    Hidradenitis Suppurativa - Pipeline by Amgen Inc, H1 2017
    Hidradenitis Suppurativa - Pipeline by Celgene Corp, H1 2017
    Hidradenitis Suppurativa - Pipeline by Cell Medica Ltd, H1 2017
    Hidradenitis Suppurativa - Pipeline by Cellceutix Corp, H1 2017
    Hidradenitis Suppurativa - Pipeline by Coherus BioSciences Inc, H1 2017
    Hidradenitis Suppurativa - Pipeline by InflaRx GmbH, H1 2017
    Hidradenitis Suppurativa - Pipeline by NeuClone Pty Ltd, H1 2017
    Hidradenitis Suppurativa - Pipeline by Novartis AG, H1 2017
    Hidradenitis Suppurativa - Pipeline by Panacea Biotec Ltd, H1 2017
    Hidradenitis Suppurativa - Pipeline by Sandoz International GmbH, H1 2017
    Hidradenitis Suppurativa - Pipeline by XBiotech Inc, H1 2017
    Hidradenitis Suppurativa - Dormant Projects, H1 2017
    Hidradenitis Suppurativa - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Hidradenitis Suppurativa, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AbbVie Inc
    Amgen Inc
    Celgene Corp
    Cell Medica Ltd
    Cellceutix Corp
    Coherus BioSciences Inc
    InflaRx GmbH
    NeuClone Pty Ltd
    Novartis AG
    Panacea Biotec Ltd
    Sandoz International GmbH
    XBiotech Inc

    Request for Sample

    Report Url http://www.reportsweb.com//hidradenitis-suppurativa-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hidradenitis-suppurativa-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hidradenitis-suppurativa-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments